top of page
About NeuroScientific
Targeting inflammatory diseases with stem cell science
NeuroScientific Biopharmaceuticals Ltd is an innovative biotechnology company dedicated to developing novel technologies targeted at immune-mediated inflammatory diseases. Founded in 2017, NeuroScientific has been developing solutions to address complex medical needs where current treatment options are limited or ineffective.
Following its announcement of the acquisition of Isopogen WA in June 2025, NeuroScientific is prioritising the use of its proprietary StemSmart™ technology in a special access program for fistulising Crohn’s disease—a particularly challenging form of the condition that resists conventional therapies. If initial outcomes are positive, the company plans to advance to a phase 1/2 clinical trial. This initiative supports NeuroScientific’s broader objective of gaining regulatory and reimbursement approvals for mesenchymal stem cell (MSC) therapy in Australia and globally, making the treatment accessible to patients with both fistulising and refractory Crohn’s disease.
Why NeuroScientific?
Robust Company & Strong Balance Sheet
$60M market cap with $7.3M in cash, strong leadership team to achieve operational and strategic objectives, and technology platform with potential in several indications
Why NeuroScientific?
StemSmart Tech Platform
A method of manufacturing MSC for the treatment of disorders with significant inflammation (ie Crohn’s disease) with a global IP position
Why NeuroScientific?
Proven Clinical Efficacy
Strong safety profile and 78% overall response (ORR)1 in refractory Crohn’s Phase 2, with ongoing SAS program in fistulising Crohn’s. Future trials anticipated, targeting lung and kidney disorders
Why NeuroScientific?
Secure Supply Chain
Expanded manufacturing capacity through tech transfer to Q-Gen to support commercialisation pathway
bottom of page